Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $171.3 million.

  • Gossamer Bio's Short-term Investments fell 4262.95% to $171.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.3 million, marking a year-over-year decrease of 4262.95%. This contributed to the annual value of $248.4 million for FY2024, which is 600.49% down from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Short-term Investments is $171.3 million, which was down 4262.95% from $186.6 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Short-term Investments registered a high of $298.6 million during Q3 2024, and its lowest value of $125.1 million during Q2 2023.
  • Over the past 4 years, Gossamer Bio's median Short-term Investments value was $186.6 million (recorded in 2025), while the average stood at $195.6 million.
  • As far as peak fluctuations go, Gossamer Bio's Short-term Investments skyrocketed by 11388.01% in 2024, and later tumbled by 4262.95% in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's Short-term Investments stood at $143.7 million in 2022, then surged by 83.93% to $264.3 million in 2023, then fell by 6.0% to $248.4 million in 2024, then plummeted by 31.05% to $171.3 million in 2025.
  • Its Short-term Investments was $171.3 million in Q3 2025, compared to $186.6 million in Q2 2025 and $228.9 million in Q1 2025.